East JE¹, Boyapati RK², Torres J^3,4, Parker CE⁵, MacDonald JK⁶, Chande N^6,7, Feagan BG^5,6,7,8. Inflamm Bowel Dis. 2019 Feb 21;25(3):472-478. doi: 10.1093/ibd/izy268.

Author information

1 Translational Gastroenterology Unit and Oxford NIHR Biomedical Research Centre, Experimental Medicine Division, Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom.

2 Department of Gastroenterology, Monash Health, Melbourne, Victoria, Australia.

3 Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

4 Hospital Beatriz Ângelo, Gastroenterology Division, Loures, Portugal.

5 Robarts Clinical Trials Inc. London, Ontario, Canada.

6 Cochrane IBD Group, University of Western Ontario, London, Ontario, Canada.

7 Division of Gastroenterology, Department of Medicine, University of Western Ontario, London, Ontario, Canada.

8 Department of Epidemiology and Biostatistics, University of Western Ontario, London, Ontario, Canada.

Abstract

A symposium organized by the Cochrane IBD Group and presented at the 2017 Digestive Disease Week annual meeting reviewed the recent literature on several controversial topics in inflammatory bowel disease (IBD) management including the efficacy of oral aminosalicylates for induction and maintenance of Crohn's disease (CD), the feasibility of drug withdrawal in patients with quiescent CD, and strategies for detecting colon cancer in patients with IBD. This article summarizes the data presented at that session.